Omidenepag isopropyl
Code | Size | Price |
---|
TAR-T16388-50mg | 50mg | £704.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16388-100mg | 100mg | £1,099.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Omidenepag isopropyl is converted to the active product Omidenepag during corneal penetration. Omidenepag isopropyl is a selective EP2 receptor agonist. Omidenepag isopropyl displays only a weak affinity for EP1, EP2, and FP receptors. Omidenepag isopropyl is under development for the treatment of glaucoma as intraocular pressure (IOP)-lowering drug.
CAS:
1187451-19-9
Formula:
C26H28N6O4S
Molecular Weight:
520.61
Pathway:
Immunology/Inflammation; GPCR/G Protein
Purity:
0.98
SMILES:
CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)n1
Target:
Prostaglandin Receptor
References
1. Kirihara T, et al. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent. Invest Ophthalmol Vis Sci.?2018 Jan 1;59(1):145-153.
2. Fuwa M, et al. Effects?of a?Novel?Selective?EP2?Receptor?Agonist,?Omidenepag?Isopropyl, on?Aqueous?Humor?Dynamics?in?Laser-Induced?Ocular?Hypertensive?Monkeys. J Ocul Pharmacol Ther.?2018 Sep;34(7):531-537.